(MedPage Today) — Whether brexpiprazole (Rexulti) is effective as adjunctive treatment for post-traumatic stress disorder (PTSD) will be debated at an FDA advisory committee meeting on Friday.
The atypical antipsychotic is under review as an…
Source link : https://www.medpagetoday.com/psychiatry/anxietystress/116564
Author :
Publish date : 2025-07-17 21:46:00
Copyright for syndicated content belongs to the linked Source.
